Food and Behaviour Research

Donate Log In

Feeding Better Mood, Behaviour, Learning and Sleep - Evidence and Best Practice - BOOK HERE

Role of human milk oligosaccharides in Group B Streptococcus colonisation

Nicholas J Andreas, Asmaa Al-Khalidi, Mustapha Jaiteh, Edward Clarke, Matthew J Hyde, Neena Modi, Elaine Holmes, Beate Kampmann, and Kirsty Mehring Le Doarel (2016) Clin Transl Immunology 5(8):  e99.  Published online 2016 Aug 26. doi: 10.1038/cti.2016.43

Web URL: Read this and related articles on the NCBI website here


Group B Streptococcus (GBS) infection is a major cause of morbidity and mortality in infants. The major risk factor for GBS disease is maternal and subsequent infant colonisation. It is unknown whether human milk oligosaccharides (HMOs) protect against GBS colonisation. HMO production is genetically determined and linked to the Lewis antigen system.
We aimed to investigate the association between HMOs and infant GBS colonisation between birth and postnatal day 90. Rectovaginal swabs were collected at delivery, as well as colostrum/breast milk, infant nasopharyngeal and rectal swabs at birth, 6 days and days 60–89 postpartum from 183 Gambian mother/infant pairs. GBS colonisation and serotypes were determined using culture and PCR. 1H nuclear magnetic resonance spectroscopy was used to characterise the mother's Lewis status and HMO profile in breast milk. 
Mothers who were Lewis-positive were significantly less likely to be colonised by GBS (X2=12.50, P<0.001). Infants of Lewis-positive mothers were less likely GBS colonised at birth (X2=4.88 P=0.03) and more likely to clear colonisation between birth and days 60–89 than infants born to Lewis-negative women (P=0.05). There was no association between Secretor status and GBS colonisation.In vitro work revealed that lacto-N-difucohexaose I (LNDFHI) correlated with a reduction in the growth of GBS.
Our results suggest that HMO such as LNDFHI may be a useful adjunct in reducing maternal and infant colonisation and hence invasive GBS disease. Secretor status offers utility as a stratification variable in GBS clinical trials.


See the associated news story: